![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Viramune |
AHFS/Drugs.com | Monograph |
MedlinePlus | a600035 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 93% ± 9% |
Metabolism | Liver |
Elimination half-life | 45 hours |
Excretion | Kidney: <6% (Parent drug) Bile duct <5% (Parent drug) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.117.250 |
Chemical and physical data | |
Formula | C15H14N4O |
Molar mass | 266.304 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1.[5] It is generally recommended for use with other antiretroviral medications.[5] It may be used to prevent mother to child spread during birth but is not recommended following other exposures.[5] It is taken by mouth.[5]
Common side effects include rash, headache, nausea, feeling tired, and liver problems.[5] The liver problems and skin rash may be severe and should be checked for during the first few months of treatment.[5][6] It appears to be safe for use during pregnancy.[5] It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.[5]
Nevirapine was approved for medical use in the United States in 1996.[5] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication.[5]
Viramune FDA label
was invoked but never defined (see the help page).Viramune XR FDA label
was invoked but never defined (see the help page).